|
1
|
Efremova M, Finotello F, Rieder D and
Trajanoski Z: Neoantigens generated by individual mutations and
their role in cancer immunity and immunotherapy. Front Immunol.
8:16792017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei
J, Ren S and Zhou C: Tumor neoantigens: From basic research to
clinical applications. J Hematol Oncol. 12:932019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong
F, Guo C, Wu X, Li Y, Li X, et al: Neoantigen vaccine: An emerging
tumor immunotherapy. Mol Cancer. 18:1282019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Zhu C and Liu Q: Toward in silico
identification of tumor neoantigens in immunotherapy. Trends Mol
Med. 25:980–992. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garcia-Garijo A, Fajardo CA and Gros A:
Determinants for neoantigen identification. Front Immunol.
10:13922019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wirth TC and Kühnel F: Neoantigen
targeting-dawn of a new era in cancer immunotherapy? Front Immunol.
8:18482017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rammensee H, Bachmann J, Emmerich NP,
Bachor OA and Stevanović S: SYFPEITHI: Database for MHC ligands and
peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parker KC, Bednarek MA and Coligan JE:
Scheme for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J Immunol.
152:163–175. 1994.PubMed/NCBI
|
|
9
|
Richters MM, Xia H, Campbell KM,
Gillanders WE, Griffith OL and Griffith M: Best practices for
bioinformatic characterization of neoantigens for clinical utility.
Genome Med. 11:562019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tran E, Ahmadzadeh M, Lu YC, Gros A,
Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al:
Immunogenicity of somatic mutations in human gastrointestinal
cancers. Science. 350:1387–1390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carey MF, Peterson CL and Smale ST:
PCR-mediated site-directed mutagenesis. Cold Spring Harb Protoc.
2013:738–742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mazzei M, Vascellari M, Zanardello C,
Melchiotti E, Vannini S, Forzan M, Marchetti V, Albanese F and
Abramo F: Quantitative real time polymerase chain reaction
(qRT-PCR) and RNAscope in situ hybridization (RNA-ISH) as effective
tools to diagnose feline herpesvirus-1-associated dermatitis. Vet
Dermatol. 30:e491–e147. 2019. View Article : Google Scholar
|
|
13
|
Thaxton JE and Li Z: To affinity and
beyond: Harnessing the T cell receptor for cancer immunotherapy.
Hum Vaccin Immunother. 10:3313–3321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kisielow P: How does the immune system
learn to distinguish between good and evil? The first definitive
studies of T cell central tolerance and positive selection.
Immunogenetics. 71:513–518. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanaseki T: Proteogenomics HLA Ligandome
analysis for cancer antigen research. Gan To Kagaku Ryoho.
46:1377–1381. 2019.(In Japanese). PubMed/NCBI
|
|
17
|
Matsushita H, Demachi-Okamura A and
Takahashi Y: Neoantigens are critical targets in naturally and
therapeutically induced immune responses to cancer. Gan To Kagaku
Ryoho. 46:1372–1376. 2019.(In Japanese). PubMed/NCBI
|
|
18
|
Garrido F and Aptsiauri N: Cancer immune
escape: MHC expression in primary tumors versus metastases.
Immunology. 158:255–266. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mandal R and Chan TA: Personalized
oncology meets immunology: The path toward precision immunotherapy.
Cancer Discov. 6:703–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu YC and Robbins PF: Cancer immunotherapy
targeting neoantigens. Semin Immunol. 28:22–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ren L, Leisegang M, Deng B, Matsuda T,
Kiyotani K, Kato T, Harada M, Park JH, Saloura V, Seiwert T, et al:
Identification of neoantigen-specific T cells and their targets:
Implications for immunotherapy of head and neck squamous cell
carcinoma. Oncoimmunology. 8:e15688132019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ,
He QM, Yang XJ, Sun Y, Mao YP, Yun JP, et al: Genomic analysis of
tumor microenvironment immune types across 14 solid cancer types:
Immunotherapeutic implications. Theranostics. 7:3585–3594. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vormehr M, Diken M, Türeci Ö, Sahin U and
Kreiter S: Personalized neo-epitope vaccines for cancer treatment.
Recent Results Cancer Res. 214:153–167. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J,
Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An
immunogenic personal neoantigen vaccine for patients with melanoma.
Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Keskin DB, Anandappa AJ, Sun J, Tirosh I,
Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E,
et al: Neoantigen vaccine generates intratumoral T cell responses
in phase Ib glioblastoma trial. Nature. 565:234–239. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cafri G, Yossef R, Pasetto A, Deniger DC,
Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, et al: Memory
T cells targeting oncogenic mutations detected in peripheral blood
of epithelial cancer patients. Nat Commun. 10:4492019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tran E, Turcotte S, Gros A, Robbins PF, Lu
YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS,
et al: Cancer immunotherapy based on mutation-specific CD4+ T cells
in a patient with epithelial cancer. Science. 344:641–645. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tran E, Robbins PF, Lu YC, Prickett TD,
Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al:
T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J
Med. 375:2255–2262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zacharakis N, Chinnasamy H, Black M, Xu H,
Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al:
Immune recognition of somatic mutations leading to complete durable
regression in metastatic breast cancer. Nat Med. 24:724–730. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shindo Y, Hazama S and Nagano H: Cancer
vaccine focused on neoantigens. Gan To Kagaku Ryoho. 46:1367–1371.
2019.(In Japanese). PubMed/NCBI
|
|
32
|
Chu Y, Liu Q, Wei J and Liu B:
Personalized cancer neoantigen vaccines come of age. Theranostics.
8:4238–4246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J, Zhao W, Wu J, Lu J, Ding Y, Wu S,
Wang H, Ding D, Mo F, Zhou Z, et al: Neoantigens derived from
recurrently mutated genes as potential immunotherapy targets for
gastric cancer. Biomed Res Int. 2019:81031422019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vilimas T: Measuring tumor mutational
burden using whole-exome sequencing. Methods Mol Biol. 2055:63–91.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smith CC, Chai S, Washington AR, Lee SJ,
Landoni E, Field K, Garness J, Bixby LM, Selitsky SR, Parker JS, et
al: Machine-learning prediction of tumor antigen immunogenicity in
the selection of therapeutic epitopes. Cancer Immunol Res.
7:1591–1604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riley TP, Keller GLJ, Smith AR, Davancaze
LM, Arbuiso AG, Devlin JR and Baker BM: Structure based prediction
of neoantigen immunogenicity. Front Immunol. 10:20472019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brennick CA, George MM, Corwin WL,
Srivastava PK and Ebrahimi-Nik H: Neoepitopes as cancer
immunotherapy targets: Key challenges and opportunities.
Immunotherapy. 9:361–371. 2017. View Article : Google Scholar : PubMed/NCBI
|
